Tetra Pharm Technologies is a Copenhagen-based biopharmaceutical company developing therapeutics that target the endocannabinoid system to treat neuropathic pain and mental health disorders. The company is led by CEO Martin Rose. It recently completed a €9M Series A and intends to use the proceeds to increase research and development capacity and expand commercial operations internationally. In 2022 the company closed several significant distribution deals across its main European markets. Tetra Pharm expects to release its first product to treat neuropathic pain in February 2023.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2023